Page 71 - Haematologica August 2018

Long-term second-line bosutinib for CP CML
erance to imatinib. Blood. 2011;118(17):
4567-4576.
11. Gambacorti-Passerini C, Brummendorf
TH, Kim DW, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intol- erance: minimum 24-month follow-up. Am J Hematol. 2014;89(7):732-742.
12. Brummendorf TH, Cortes JE, Khoury HJ, et al. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. Br J Haematol. 2016; 172(1):97-110.
13. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chron- ic phase chronic myeloid leukemia patients
with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010;95(2):232-240.
14. Shah NP, Kantarjian H, Kim D-W, et al. Six- year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic- phase chronic myeloid leukemia (CML-CP) receiving dasatinib. J Clin Oncol. 2012;30 (15_suppl):6506.
15. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilo- tinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009;27 (3):469-471.
16. ICLUSIG® (ponatinib). Full Prescribing Information. ARIAD Pharmaceuticals Inc., Cambridge, MA, USA, 2016.
17. Cortes JE, Jean Khoury H, Kantarjian H, et al. Long-term evaluation of cardiac and vas- cular toxicity in patients with Philadelphia
chromosome-positive leukemias treated with bosutinib. Am J Hematol. 2016;91(6): 606-616.
18. Brummendorf TH, Cortes JE, de Souza CA, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month fol- low-up of the BELA trial. Br J Haematol. 2015;168(1):69-81.
19. Cortes JE, Gambacorti-Passerini C, Kim DW, et al. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. Clin Lymphoma Myeloma Leuk. 2017;17(10): 684-695.
20. Marcolino MS, Boersma E, Clementino NC, et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol. 2011;22(9):2073-2079.
haematologica | 2018; 103(8)
1307